The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab

European Journal of Cancer

Volumn 44, Issue 7, 2008, Pages 912-920

  Marty, Michel ^a   Pivot, Xavier ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Angiogenesis; Bevacizumab; Breast cancer; Monoclonal antibody; Tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)

Indexed keywords

AXITINIB; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; LAPATINIB; LETROZOLE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NAVELBINE; PACLITAXEL; PAZOPANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB; VATALANIB;

ANGIOGENESIS; ARTICLE; BLEEDING; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; NAUSEA AND VOMITING; NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42549173671     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.01.005     Document Type: Article

References (77)

1. Winer E.P., Morrow M., Osborne C.K., and Harris J.R. Malignant tumors of the breast. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology (2001), Lippincott, Williams and Wilkins, Philadelphia 651-717
2. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
3. Jain R.K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29 (2002) 3-9
4. Achen M.G., and Stacker S.A. The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int J Exp Pathol 79 (1998) 255-265
5. Gerwins P., Skoldenberg E., and Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 34 (2000) 185-194
6. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., and Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5 (1991) 1806-1814
7. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266 (1991) 11947-11954
8. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56 (1999) 794-814
9. Tuder R.M., Flook B.E., and Voelkel N.F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95 (1995) 1798-1807
10. Petit A.M., Rak J., Hung M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151 (1997) 1523-1530
11. Ikeda E., Achen M.G., Breier G., and Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270 (1995) 19761-19766
12. Rak J., Mitsuhashi Y., Bayko L., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55 (1995) 4575-4580
13. Bouvet M., Ellis L.M., Nishizaki M., et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58 (1998) 2288-2292
14. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
15. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992) 989-991
16. Terman B.I., Dougher-Vermazen M., Carrion M.E., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187 (1992) 1579-1586
17. Folkman J., Cole P., and Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164 (1966) 491-502
18. Borgstrom P., Gold D.P., Hillan K.J., and Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19 (1999) 4203-4214
19. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
20. von Marschall Z., Cramer T., Hocker M., et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119 (2000) 1358-1372
21. Neufeld G., Kessler O., Vadasz Z., and Gluzman-Poltorak Z. The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors. Surg Oncol Clin N Am 10 (2001) 339-356
22. Gabrilovich D., Ishida T., Oyama T., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998) 4150-4166
23. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
24. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
25. Inai T., Mancuso M., Hashizume H., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165 (2004) 35-52
26. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
27. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
28. Wildiers H., Guetens G., De Boeck G., et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88 (2003) 1979-1986
29. Baluk P., Hashizume H., and McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15 (2005) 102-111
30. Osusky K.L., Hallahan D.E., Fu A., Ye F., Shyr Y., and Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7 (2004) 225-233
31. Vosseler S., Mirancea N., Bohlen P., Mueller M.M., and Fusenig N.E. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 65 (2005) 1294-1305
32. Brown L.F., Berse B., Jackman R.W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26 (1995) 86-91
33. Gasparini G., Toi M., Gion M., et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89 (1997) 139-147
34. Linderholm B., Tavelin B., Grankvist K., and Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16 (1998) 3121-3128
35. Linderholm B., Lindh B., Tavelin B., Grankvist K., and Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 89 (2000) 51-62
36. Linderholm B.K., Lindh B., Beckman L., et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 4 (2003) 340-347
37. Foekens J.A., Peters H.A., Grebenchtchikov N., et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61 (2001) 5407-5414
38. Ragaz J., Miller K.D., Badve S., et al. Adverse association of expressed vascular endothelial growth factor (VEGF), Her2, Cox2, uPA and EMSY with long-term outcome of stage I-III breast cancer (BrCa). Results from the British Columbia Tissue Microarray Project. J Clin Oncol 22 Suppl. 14 (2004) 8S [abstract 524]
39. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., and Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99 (2002) 4349-4354
40. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000) 5565-5570
41. Gupta V.K., Jaskowiak N.T., Beckett M.A., et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8 (2002) 47-54
42. Cascinu S., Graziano F., Valentini M., et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 12 (2001) 239-244
43. Borgstrom P., Hillan K.J., Sriramarao P., and Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56 (1996) 4032-4039
44. Epstein M., Ayala R.E., Tchekmedyian N., Borgstrom P., Pegram M., and Slamon D.J. HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 76 Suppl. 1 (2002) S143 [abstract 570]
45. Traina T., Rugo H., Caravelli J., et al. Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model. J Clin Oncol 25 Suppl. 18 (2007) 44S [abstract 1049]
46. Cobleigh M.A., Langmuir V.K., Sledge G.W., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 (2003) 117-124
47. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
48. Miller K.D., Wang M., Gralow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). N Engl J Med 357 (2007) 2666-2676
49. F. Hoffmann-La Roche Ltd. Avastin summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/H-582-PI-en.pdf [accessed 14.03.08].
50. F. Hoffmann-La Roche, data on file.
51. Ramaswamy B., Elias A.D., Kelbick N.T., et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12 (2006) 3124-3129
52. Chan D., Allen H., Hu E., et al. Phase 2 study of docetaxel (D) plus bevacizumab (B) in Her/2 negative metastatic breast carcinoma (MBC). J Clin Oncol 24 Suppl. 18 (2006) 605S [abstract 13047]
53. Burstein H.J., Parker L.M., Savoie J., et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 76 Suppl. 1 (2002) S115 [abstract 446]
54. Burstein H.J., Spigel D.R., Kindsvogel K., et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 94 Suppl. 1 (2005) S6 [abstract 4]
55. Traina T.A., Rugo H., Caravelli J., et al. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol 24 Suppl. 18 (2006) 133S [abstract 3050]
56. Pegram M., Yeon C., Durna L.N., et al. Phase 1 combined biologic therapy of breast cancer using 2 humanized monoclonal antibodies directed against HER2 protooncogene and vascular endothelial growth factor. Breast Cancer Res Treat 88 Suppl. 1 (2004) S124 [abstract 3039]
57. Pegram M., Chan D., Dichmann R.A., et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 100 Suppl. 1 (2006) S28 [abstract 301]
58. Jubb A.M., Hurwitz H.I., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24 (2006) 217-227
59. Ince W.L., Jubb A.M., Holden S.N., et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97 (2005) 981-989
60. Rugo H.S., Dickler M.N., Scott J.H., et al. Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation. J Clin Oncol 23 Suppl. 16 (2005) 10S [abstract 525]
61. Rugo H.S., Dickler M.N., Traina T.A., et al. Change in circulating endothelial cells (CECs) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B). J Clin Oncol 24 Suppl. 18 (2006) 130S [abstract 3039]
62. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 Suppl. 3 (2005) 25-33
63. Lyons J.A., Silverman P., Remick S., et al. Toxicity results and early outcome data on a randomized phase II study of docetaxel +/- bevacizumab for locally advanced, unresectable breast cancer. J Clin Oncol 24 Suppl. 18 (2006) 133S [abstract 3049]
64. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
65. Yoshiji H., Harris S.R., and Thorgeirsson U.P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57 (1997) 3924-3928
66. Abrams T.J., Murray L.J., Pesenti E., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2 (2003) 1011-1021
67. Murray L.J., Abrams T.J., Long K.R., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20 (2003) 757-766
68. Miller K.D., Burstein H.J., Elias A.D., et al. Phase II study of SU 11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol 23 Suppl. 16 (2005) 19S [abstract 563]
69. Bianchi G., Loibl S., Zamagni C., et al. A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer. Eur J Cancer Suppl 3 (2005) 78 [abstract 276]
70. Moreno-Aspitia A., Hillman D.W., Wiesenfeld M., et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J Clin Oncol 24 Suppl. 18 (2006) 22S [abstract 577]
71. Miller K.D., Trigo J.M., Wheeler C., et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11 (2005) 3369-3376
72. Rugo H.S., Stopeck A., Joy A.A., et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol 25 Suppl. 18 (2007) 18S [abstract 1003]
73. Nabholtz J.M., Falkson C., Campos D., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21 (2003) 968-975
74. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 (1999) 2341-2354
75. Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19 (2001) 1707-1715
76. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812-2823
77. Melemed AS, O'Shaughnessy J, Nag S, et al. Phase III study of gemcitabine plus paclitaxel compared with paclitaxel alone in patients with unresectable, locally recurrent, or metastatic breast cancer. In: Presented at 2007 Breast cancer symposium, 7-8 September 2007, San Francisco (CA) [abstract 150]. ; 2007 [accessed 27.10.2007].